ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.-78.3%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
ATAI vs MNMD vs CMPS vs CYBN vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-63.5%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-75.4%
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-91.4%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-7.5%
ATAI vs MNMD vs CMPS vs CYBN vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ATAI | MNMD | CMPS | CYBN | ACAD |
|---|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology | Medical - Care Facilities | Biotechnology | Biotechnology |
| Market Cap | $964M | $2.04B | $902M | $304M | $3.86B |
| Revenue (TTM) | $3M | $0.00 | $0.00 | $0.00 | $1.10B |
| Net Income (TTM) | $-154M | $-238M | $-288M | $-123M | $376M |
| Gross Margin | -259.1% | — | — | — | 91.5% |
| Operating Margin | -34.6% | — | — | — | 7.4% |
| Forward P/E | — | — | — | — | 50.9x |
| Total Debt | $25M | $0.00 | $21M | $0.00 | $52M |
| Cash & Equiv. | $18M | $258M | $150M | $135M | $178M |
ATAI vs MNMD vs CMPS vs CYBN vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ATAI
MNMD
CMPS
CYBN
ACAD
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Atai Beckley N.V (ATAI) | 100 | 21.7 | -78.3% |
| Mind Medicine (Mind… (MNMD) | 100 | 36.5 | -63.5% |
| COMPASS Pathways plc (CMPS) | 100 | 24.6 | -75.4% |
| Cybin Inc. (CYBN) | 100 | 8.6 | -91.4% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 92.5 | -7.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ATAI vs MNMD vs CMPS vs CYBN vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 4 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ATAI
Atai Beckley N.V
The Healthcare Pick
ATAI plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 5.1% 10Y total return vs ACAD's -22.9%
- +214.0% vs CYBN's -1.9%
Best for: long-term compounding
CMPS
COMPASS Pathways plc
The Healthcare Pick
CMPS lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
CYBN
Cybin Inc.
The Healthcare Pick
Among these 5 stocks, CYBN doesn't own a clear edge in any measured category.
Best for: healthcare exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.26
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- Lower volatility, beta 1.26, Low D/E 4.3%, current ratio 3.83x
- Beta 1.26, current ratio 3.83x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ACAD | 11.9% revenue growth vs MNMD's -96.9% |
| Quality / Margins | ACAD | 34.3% margin vs ATAI's -51.1% |
| Stability / Safety | ACAD | Beta 1.26 vs MNMD's 1.68 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs CYBN's -1.9% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs CMPS's -106.8% |
ATAI vs MNMD vs CMPS vs CYBN vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2018
ATAI vs MNMD vs CMPS vs CYBN vs ACAD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGCYBN
Who Leads Where
ACAD leads in 3 of 6 categories
MNMD leads 1 • ATAI leads 0 • CMPS leads 0 • CYBN leads 0 • 1 tied
Explore the data ↓CYBNCybin Inc.
0leads
CMPSCOMPASS Pathways plc
0leads
ATAIAtai Beckley N.V
0leads
MNMDMind Medicine (MindMe…
1leads
ACADACADIA Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs MNMDvs ATAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD4/6
Valuation MetricsMultiples, price ratios, and targets
ACAD2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and CYBN operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to ATAI's -51.1%. On growth, ATAI holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $0 | $0 | $0 | $1.1B |
| EBITDAEarnings before interest/tax | -$103M | -$191M | -$179M | -$147M | $96M |
| Net IncomeAfter-tax profit | -$154M | -$238M | -$288M | -$123M | $376M |
| Free Cash FlowCash after capex | -$90M | -$174M | -$157M | -$106M | $212M |
| Gross MarginGross profit ÷ Revenue | -2.6% | — | — | — | +91.5% |
| Operating MarginEBIT ÷ Revenue | -34.6% | — | — | — | +7.4% |
| Net MarginNet income ÷ Revenue | -51.1% | — | — | — | +34.3% |
| FCF MarginFCF ÷ Revenue | -29.9% | — | — | — | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.7% | — | — | — | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -75.0% | -163.0% | -58.7% | -8.2% | -81.8% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
ACAD leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| Market CapShares × price | $964M | $2.0B | $902M | $304M | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $971M | $1.8B | $774M | $205M | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -4.31x | -10.04x | -3.05x | -13.66x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 26.91x |
| Price / SalesMarket cap ÷ Revenue | 3130.37x | — | — | — | 3.61x |
| Price / BookPrice ÷ Book value/share | 5.51x | 5.56x | — | 6.52x | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 36.74x |
ACAD leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-3 for CMPS. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATAI's 0.21x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs CMPS's 2/9, reflecting solid financial health.
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -96.4% | -102.5% | -3.4% | -81.0% | +35.6% |
| ROA (TTM)Return on assets | -64.3% | -70.7% | -106.8% | -58.3% | +26.2% |
| ROICReturn on invested capital | -45.0% | -3.9% | — | -115.8% | +10.0% |
| ROCEReturn on capital employed | -50.4% | -52.2% | -2.5% | -54.1% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 2 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.21x | — | — | — | 0.04x |
| Net DebtTotal debt minus cash | $7M | -$258M | -$129M | -$135M | -$126M |
| Cash & Equiv.Liquid assets | $18M | $258M | $150M | $135M | $178M |
| Total DebtShort + long-term debt | $25M | $0 | $21M | $0 | $52M |
| Interest CoverageEBIT ÷ Interest expense | -68.93x | -21.81x | -52.40x | — | — |
ACAD leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $968 for CYBN. Over the past 12 months, MNMD leads with a +214.0% total return vs CYBN's -1.9%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs CYBN's -20.5% — a key indicator of consistent wealth creation.
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +3.6% | +51.7% | +43.4% | -26.4% | -13.7% |
| 1-Year ReturnPast 12 months | +188.5% | +214.0% | +151.1% | -1.9% | +52.4% |
| 3-Year ReturnCumulative with dividends | +99.5% | +510.3% | +11.0% | -49.8% | +4.7% |
| 5-Year ReturnCumulative with dividends | -79.8% | -57.9% | -72.4% | -90.3% | +7.1% |
| 10-Year ReturnCumulative with dividends | -47.7% | +512.1% | -67.6% | -99.7% | -22.9% |
| CAGR (3Y)Annualised 3-year return | +25.9% | +82.7% | +3.5% | -20.5% | +1.5% |
MNMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNMD and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than MNMD's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs ATAI's 59.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.48x | 1.68x | 1.33x | 1.52x | 1.26x |
| 52-Week HighHighest price in past year | $6.75 | $21.09 | $10.21 | $9.83 | $27.81 |
| 52-Week LowLowest price in past year | $1.29 | $6.03 | $2.25 | $5.50 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +59.4% | +98.1% | +92.0% | +62.0% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 64.9 | 68.1 | 35.5 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 6.0M | 792K | 3.7M | 292K | 1.8M |
Evenly matched — MNMD and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ATAI as "Buy", MNMD as "Buy", CMPS as "Buy", CYBN as "Buy", ACAD as "Buy". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | CYBNCybin Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | $20.00 | $17.83 | — | $34.78 |
| # AnalystsCovering analysts | 4 | 1 | 13 | 4 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). MNMD leads in 1 (Total Returns). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 3 of 6 categories
Loading custom metrics...
ATAI vs MNMD vs CMPS vs CYBN vs ACAD: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ATAI or MNMD or CMPS or CYBN or ACAD a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -1. 9% for Atai Beckley N. V (ATAI). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Atai Beckley N. V (ATAI) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ATAI or MNMD or CMPS or CYBN or ACAD?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ATAI or MNMD or CMPS or CYBN or ACAD?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 26β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 34% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 21% for Atai Beckley N. V — giving it more financial flexibility in a downturn.
04Which is growing faster — ATAI or MNMD or CMPS or CYBN or ACAD?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus -1. 9% for Atai Beckley N. V (ATAI). On earnings-per-share growth, the picture is similar: Cybin Inc. grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ATAI or MNMD or CMPS or CYBN or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ATAI or MNMD or CMPS or CYBN or ACAD more undervalued right now?
Analyst consensus price targets imply the most upside for ATAI: 199.
3% to $12. 00.
07Which pays a better dividend — ATAI or MNMD or CMPS or CYBN or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ATAI or MNMD or CMPS or CYBN or ACAD better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cybin Inc. (CYBN) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -22. 9%, CYBN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ATAI and MNMD and CMPS and CYBN and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ATAI is a small-cap quality compounder stock; MNMD is a small-cap quality compounder stock; CMPS is a small-cap quality compounder stock; CYBN is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.